Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Search PHGKB:

Last Posted: May 23, 2023
spot light Highlights

An artificial intelligence based app for skin cancer detection evaluated in a population based setting.
Anna M Smak Gregoor et al. NPJ Digit Med 2023 5 (1) 90

Artificial intelligence (AI) based algorithms for classification of suspicious skin lesions have been implemented in mobile phone apps (mHealth), but their effect on healthcare systems is undocumented. In 2019, a large health insurance company offered 2.2 million adults free access to an mHealth app for skin cancer detection. To study the impact on dermatological healthcare consumption, we conducted a retrospective population-based pragmatic study. We matched 18,960 mHealth-users who completed at least one successful assessment with the app to 56,880 controls.

Personalized vaccine for melanoma may stave off cancer’s return
J Kaiser, Science, April 16, 2023

A novel cancer vaccine tailored to genetic changes in a person’s tumor is showing promise in the clinic. In a study of about 150 people who had surgery for melanoma, a type of skin cancer, those given a personalized vaccine along with an immunotherapy drug were more likely to remain free of cancer 18 months later than patients who did not receive the vaccine.

Preoperative immune-therapy combination shows promise in skin cancer
Nature Clinical Briefings, October 26, 2022

Treatment with the drugs relatlimab and nivolumab before the surgical removal of a type of cancer called melanoma resulted in tumours becoming inviable in 57% of individuals, and no severe adverse effects were observed. People with a favourable treatment response had a better survival outcome than did those who did not respond.

Neurofibromatosis Type 1 and Risk of Skin Cancer
J Trinh et al, JAMA Dermatology, August 24, 2022

This study found increased odds of melanoma, BCC, and SCC in patients with NF1. Whole-exome sequencing has established NF1 as the third most frequently mutated gene in melanomas.3 About 12% to 18% of melanomas and 45% to 93% of desmoplastic melanomas harbor NF1 alterations.

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.